Use of myeloid colony-stimulating factors in neonates with septicemia

Current Opinion in Pediatrics

Volumn 14, Issue 1, 2002, Pages 91-94

  Bernstein, Hilton M ^a   Calhoun, Darlene A ^a   Christensen, Robert D ^a  

^a FWC FL Marine Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; DRUG ELIMINATION; DRUG HALF LIFE; EARLY DIAGNOSIS; HUMAN; INFECTION SENSITIVITY; MORTALITY; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; OSTEOPOROSIS; PREMATURITY; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; THROMBOCYTOPENIA;

CLINICAL TRIALS; COLONY-STIMULATING FACTORS; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFANT, NEWBORN; SEPSIS;

EID: 0036186799     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200202000-00016     Document Type: Review

References (39)

1. A randomized trial of granulocyte macrophage colony-stimulating factor in neonates with sepsis and neutropenia
2. Occurrence of nosocomial bloodstream infections in six neonatal intensive care units
3. Risk factors for nosocomial sepsis in newborn intensive and intermediate care units
4. Novel approaches to the prevention and therapy of neonatal bacterial sepsis
5. Human developmental biology of granulocyte colony-stimulating factor
6. Neonatal neutrophil host defense
7. Lenograstim: An update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings
8. Granulocyte colony stimulating factors: How different are they? How to make a decision?
9. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: Comparison with single and multiple daily doses of filgrastim
10. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim)
11. NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor
12. Proliferative activity of rG-CSFs in cell line bioassays
13. In vitro comparison of the biologic potency of glycosylated versus non-glycosylated rG-CSF
14. A randomized, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: Significant induction of peripheral and bone marrow neutrophilia
15. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins
16. Characterization and stability of N-terminally PEGylated rhG-CSF
17. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats
18. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans
19. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy
20. Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons
21. The role of hematopoietic growth factors in transfusion medicine
22. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation
23. Haemopoietic colony stimulating factors for preterm neonates
24. The effect of three human recombinant hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte oxidative activity
25. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia
26. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis
27. A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia
28. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis
29. The in vivo effect of recombinant human granulocyte colony-stimulating factor in neutropenic neonates with sepsis
30. Administration of recombinant granulocyte colony-stimulating factor to neonates with septicemia: A meta-analysis
31. A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life
32. Granulocyte colony-stimulating factor treatment for neonatal neutropenia
33. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children
34. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: Significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils
35. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias
36. A point mutation in the granulocyte colony-stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the over expression of a novel G-CSF-R isoform
37. Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation
38. High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome)
39. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization